On this page
CICLOPIROX
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Ciclopirox | 7.7 mg/g | 250344 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Decreased DNA Replication [PE] | PE | 5 members — no class page |
| Decreased Protein Synthesis [PE] | PE | 7 members — no class page |
| Decreased RNA Replication [PE] | PE | 5 members — no class page |
| Protein Synthesis Inhibitors [MoA] | MoA | 7 members — no class page |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 078266-001 | CICLOPIROX | GEL | CICLOPIROX | Prescription | AB |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 2 | Labeling | Approved | October 14, 2015 | Standard |
| Original application | 1 | Approved | January 7, 2009 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260123). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Superficial Dermatophyte Infections Ciclopirox Gel, 0.77% is indicated for the topical treatment of interdigital tinea pedis and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum . Seborrheic Dermatitis Ciclopirox Gel, 0.77% is indicated for the topical treatment of seborrheic dermatitis of the scalp.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Superficial Dermatophyte Infections Gently massage Ciclopirox Gel, 0.77% into the affected areas and surrounding skin twice daily, in the morning and evening immediately after cleaning or washing the areas to be treated. Interdigital tinea pedis and tinea corporis should be treated for 4 weeks. If a patient shows no clinical improvement after 4 weeks of treatment, the diagnosis should be reviewed. Seborrheic Dermatitis of the Scalp Apply Ciclopirox Gel, 0.77% to affected scalp areas twice daily, in the morning and evening for 4 weeks. Clinical improvement usually occurs within the first week with continuing resolution of signs and symptoms through the fourth week of treatment. If a patient shows no clinical improvement after 4 weeks of treatment, the diagnosis should be reviewed.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Ciclopirox Gel, 0.77% is contraindicated in individuals who have shown hypersensitivity to any of its components.
Warnings
openFDA Drug LabelingWARNINGS Ciclopirox Gel, 0.77% is not for ophthalmic, oral, or intravaginal use. Keep out of reach of children.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS In clinical trials, 140 (39%) of 359 subjects treated with Ciclopirox Gel, 0.77% reported adverse experiences, irrespective of relationship to test materials, which resulted in 8 subjects discontinuing treatment. The most frequent experience reported was skin burning sensation upon application, which occurred in approximately 34% of seborrheic dermatitis patients and 7% of tinea pedis patients. Adverse experiences occurring between 1% to 5% were contact dermatitis and pruritus. Other reactions that occurred in less than 1% included dry skin, acne, rash, alopecia, pain upon application, eye pain, and facial edema.
Mechanism of Action
openFDA Drug LabelingMechanism of Action Ciclopirox is a hydroxypyridone antifungal agent although the relevance of this property for the indication of seborrheic dermatitis is not known. Ciclopirox acts by chelation of polyvalent cations (Fe 3+ or Al 3+ ), resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell.
Description
openFDA Drug LabelingDESCRIPTION Ciclopirox Gel, 0.77% contains a synthetic antifungal agent, ciclopirox. It is intended for topical dermatologic use only. Each gram of Ciclopirox Gel, 0.77% contains 7.70 mg of ciclopirox in a gel consisting of Purified Water USP, Isopropyl Alcohol USP, Octyldodecanol NF, Dimethicone Copolyol 190, Carbomer 980, Sodium Hydroxide NF, and Docusate Sodium USP. Ciclopirox Gel, 0.77% is a white, slightly fluid gel. The chemical name for ciclopirox is 6-cyclohexyl-1-hydroxy-4-methyl-2(1 H )- pyridinone, with the empirical formula C 12 H 17 NO 2 and a molecular weight of 207.27. The CAS Registry Number is [29342-05-0]. The chemical structure is: Ciclopirox Gel Structural Formula
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Ciclopirox gel 0.77% is supplied in aluminum tubes and LDPE tubes. 30 g tubes (NDC 68462-455-35), 45 g tubes (NDC 68462-455-47) and 100 g tubes (NDC 68462-455-94). Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Distributed by: Glenmark Pharmaceuticals Inc., USA Elmwood Park, NJ 07407 Questions? 1 (888)721-7115 www.glenmarkpharma-us.com April 2025 glenmarklogo
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: CICLOPIROX. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 63629-8620-1 | 63629-8620 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8620-1) / 30 g in 1 TUBE | January 7, 2009 |
| 63629-8621-1 | 63629-8621 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8621-1) / 45 g in 1 TUBE | January 7, 2009 |
| 63629-8622-1 | 63629-8622 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8622-1) / 100 g in 1 TUBE | January 7, 2009 |
| 71335-2757-1 | 71335-2757 | Bryant Ranch Prepack | 30 g in 1 TUBE (71335-2757-1) | August 8, 2025 |
| 72162-1126-1 | 72162-1126 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1126-1) / 100 g in 1 TUBE | March 11, 2024 |
| 72162-1126-2 | 72162-1126 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1126-2) / 45 g in 1 TUBE | March 11, 2024 |
| 72162-1126-3 | 72162-1126 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1126-3) / 30 g in 1 TUBE | March 11, 2024 |
| 68462-455-35 | 68462-455 | Glenmark Pharmaceuticals Inc., USA | 30 g in 1 TUBE (68462-455-35) | February 29, 2012 |
| 68462-455-47 | 68462-455 | Glenmark Pharmaceuticals Inc., USA | 45 g in 1 TUBE (68462-455-47) | February 29, 2012 |
| 68462-455-94 | 68462-455 | Glenmark Pharmaceuticals Inc., USA | 100 g in 1 TUBE (68462-455-94) | February 29, 2012 |
| 0574-2061-01 | 0574-2061 | Padagis US LLC | 1 TUBE in 1 CARTON (0574-2061-01) / 100 g in 1 TUBE | January 7, 2009 |
| 0574-2061-30 | 0574-2061 | Padagis US LLC | 1 TUBE in 1 CARTON (0574-2061-30) / 30 g in 1 TUBE | January 7, 2009 |
| 0574-2061-45 | 0574-2061 | Padagis US LLC | 1 TUBE in 1 CARTON (0574-2061-45) / 45 g in 1 TUBE | January 7, 2009 |
| 63629-8620 | 63629-8620 | Bryant Ranch Prepack | — | January 7, 2009 |
| 63629-8621 | 63629-8621 | Bryant Ranch Prepack | — | January 7, 2009 |
| 63629-8622 | 63629-8622 | Bryant Ranch Prepack | — | January 7, 2009 |
| 71335-2757 | 71335-2757 | Bryant Ranch Prepack | — | February 29, 2012 |
| 72162-1126 | 72162-1126 | Bryant Ranch Prepack | — | January 7, 2009 |
| 68462-455 | 68462-455 | Glenmark Pharmaceuticals Inc., USA | — | February 29, 2012 |
| 0574-2061 | 0574-2061 | Padagis US LLC | — | January 7, 2009 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.